A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects
Information source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Levofloxacin oral suspension (Drug); Levofloxacin oral solution (Drug); Levofloxacin marketed tablet formulations (Drug)
Phase: Phase 1
Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Official(s) and/or principal investigator(s):
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The primary objective of the study was to assess the bioequivalence of the oral suspension
formulation, the oral solution formulation, and the marketed tablet formulation of
levofloxacin, with the marketed tablet as the reference.
Official title: An Open-Label, Randomized, 3-Way Crossover Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects
Study design: Treatment, Randomized, Open Label, Crossover Assignment, Bio-equivalence Study
Primary outcome: Assessment of the bioequivalence of the oral suspension formulation, the oral solution formulation, and the marketed tablet formulation of levofloxacin, on Days 1, 2, and 3, using the marketed tablet as the reference.
Secondary outcome: Assessment of the bioequivalence of the oral suspension and solution formulations, on Days 1, 2, and 3, using the suspension formulation as the reference.
In this single-dose study conducted at at single center, 3 oral formulations of levofloxacin
(tablet, suspension, and solution) were assessed for their bioequivalence in healthy men and
women aged 18 to 55 years old. Subjects were assigned different treatments based on chance;
both the researcher and the study participant knew the treatment being administered. The
study consisted of a screening period, 3 open-label treatment periods separated by washout
periods of at least 4 days between doses, and a post-treatment period. Subjects received a
single dose of all 3 study formulations, administered as a single dose of each formulation on
Day 1 of each treatment period. Blood samples were collected on Days 1, 2, and 3 of each
treatment period immediately before dosing and at 0. 25, 0. 5, 0. 75, 1, 1. 5, 2, 4, 6, 10, 14,
24, 30, 36, and 48 hours after dosing for measurement of levofloxacin concentration. Subjects
were admitted to the study site prior to dosing and remained through the 48-hour measurements
on Day 3. The post-treatment period included physical examination and clinical laboratory
testing to ensure subject safety before being discharged from the study. Safety evaluations,
including adverse event monitoring, standard clinical laboratory evaluations (hematology,
serum chemistry, and urinalysis), vital sign monitoring, and physical examinations, were
monitored throughout the study. Two cohorts of 36 subjects each were enrolled in the study.
The first cohort received a single dose of study drug and completed Period 1; the study was
then stopped and reinitiated. Subjects from the first cohort completed early termination
procedures; their data were included in safety analyses, however, no blood samples for
levofloxacin concentrations were analyzed or included in pharmacokinetic analysis.
Thirty-four subjects in the second cohort completed all study procedures.
Levofloxacin oral suspension (125 mg/5 mL), levofloxacin oral solution (125 mg/5 mL), and
levofloxacin tablet (500 mg) administered on Day 1 of each treatment period.
Minimum age: 18 Years.
Maximum age: 55 Years.
- Men and women
- Aged 18 to 55 years
- BMI between 18 and 30 kg/m2
- No prescription or over-the-counter medications for previous 14 days
- Negative tests for drug and alcohol abuse, HIV, hepatitis B and hepatitis C
- And Healthy based on medical history, physical examination, 12-lead
electrocardiograms, toxicology, antigen, and antibody screens, and clinical laboratory
- Allergic reaction to quinolones
- Clinically significant ECG or clinical laboratory abnormalities
- Creatinine clearance <=80 mL/min
- Acute illness within 7 days
- Nicotine use within 1 year
- Receipt of experimental drug or device within 60 days
- Pregnant or breastfeeding
Locations and Contacts
An open-label, randomized, 3-way crossover study to evaluate the bioequivalence of an oral suspension formulation, an oral solution formulation, and the marketed tablet formulation of Levofloxacin in healthy subjects
Starting date: October 2002
Ending date: November 2002
Last updated: January 25, 2008